Updated COVID-19 Booster Recommendations for Children Five Years and Older
Today, CDC’s Director Dr. Rochelle Walensky released a statement and signed a decision memo recommending updated (bivalent) COVID-19 boosters for children five years and older. FDA amended the Emergency Use Authorizations (EUAs) of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups.
- The Moderna COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to six years of age.
- Please be aware the injection dose volume changes with age. Review the new EUA for guidance.
- Be sure to select the correct intent when ordering in Philavax to ensure you get the correct ancillary kits – pediatric vs adult.
- This product is already out in the field and you may begin administering to the pediatric population today. NDC: 80777-0282-99
- The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to five years of age.
- Deliveries for pre-orders will begin on Monday. Any order placed after 9/28, the pre-ordering deadline, will be delivered the following weeks after the pre-orders arrive.
- NDC: 59267-0565-02
With today’s authorization, the monovalent Pfizer-BioNTech COVID-19 Vaccine is no longer authorized as a booster dose for individuals five through 11 years of age. Both the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine continue to be authorized for primary series administration in individuals six months of age and older.